Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
Top Cited Papers
- 8 July 2010
- journal article
- research article
- Published by Elsevier
- Vol. 11 (8) , 753-762
- https://doi.org/10.1016/s1470-2045(10)70130-3
Abstract
No abstract availableThis publication has 30 references indexed in Scilit:
- Analysis of PTEN, BRAF, and EGFR Status in Determining Benefit From Cetuximab Therapy in Wild-Type KRAS Metastatic Colon CancerJournal of Clinical Oncology, 2009
- KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancerBritish Journal of Cancer, 2009
- Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancerBritish Journal of Cancer, 2009
- PIK3CA Mutations Are Not a Major Determinant of Resistance to the Epidermal Growth Factor Receptor Inhibitor Cetuximab in Metastatic Colorectal CancerClinical Cancer Research, 2009
- PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon CancerJournal of Clinical Oncology, 2009
- PIK3CA Mutations in Colorectal Cancer Are Associated with Clinical Resistance to EGFR-Targeted Monoclonal AntibodiesCancer Research, 2009
- CRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsOncogene, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Helical domain and kinase domain mutations in p110α of phosphatidylinositol 3-kinase induce gain of function by different mechanismsProceedings of the National Academy of Sciences, 2008
- Targeting RAS signalling pathways in cancer therapyNature Reviews Cancer, 2003